Understanding these differences by choosing natural or short-lived synthetic ligands to promote the desired effect, or by the creation of novel AHR ligands that selectively induce beneficial effects may provide new and exciting therapies for the treatment of eye disease. The gene discussed is AHR; the disease is eye disorder.